Aducanumab: a look two years after its approval

Abstract

Alzheimer's disease (AD) is the leading cause of dementia worldwide, representing an important public health problem. While deaths from cardiovascular diseases have decreased, those attributed to AD have increased in recent years and to date there is no curative treatment. This is why the development of an effective treatment has become a global priority. Aducanumab is a human anti-amyloid β monoclonal antibody approved for the treatment of AD in June 2021 by the FDA, without the expected clinical efficacy in phase III trials. This review analyzes the history of its controversial acceptance, implications, and prospects for future treatment.